Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07115654 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BCMA/CD3 BsAb Therapy for POEMS Syndrome

Name: BCMA/CD3 BsAb Therapy for POEMS Syndrome — clinical trial record (NCT07115654)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Started2025-08-04

View on ClinicalTrials.gov ↗

Amendment history

2026-09-30

Recruitment opened

Institute of Hematology & Blood Diseases Hospital, China

318 trials monitored

See 9 trials at risk

This is a prospective, single-arm, investigator-initiated clinical trial evaluating the safety and efficacy of a BCMA/CD3 bispecific antibody (CM336) in patients with POEMS syndrome.

Trial Details

NCT Number	NCT07115654
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	POEMS Syndrome
Enrollment	10 participants
Start Date	2025-08-04
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-29